{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:38:43Z","timestamp":1758148723673,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":201,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.rmcr.2025.102267","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:12:01Z","timestamp":1753225921000},"page":"102267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Using delafloxacin, a 4th generation fluoroquinolone, in combination with nebulised tobramycin to eradicate Pseudomonas aeruginosa in cystic fibrosis"],"prefix":"10.1016","volume":"57","author":[{"given":"Michael Kevin","family":"Dooney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Etumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2025.102267_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmcr.2025.102267_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcf.2014.06.003","article-title":"Open label study of inhaled aztreonam for pseudomonas eradication in children with cystic fibrosis: the ALPINE study","volume":"14","author":"Tiddens","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmcr.2025.102267_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid0901.020277","article-title":"Maintaining fluoroquinolone class efficacy: review of influencing factors","volume":"1","author":"Scheld","year":"2003","journal-title":"Emerg. Infect. Dis."},{"issue":"S1","key":"10.1016\/j.rmcr.2025.102267_bib4","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/S1569-1993(22)00478-7","article-title":"P147 In vitro sensitivity of Gram-negative cystic fibrosis isolates to a 4th generation fluoroquinolone","volume":"21","author":"Farrell","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmcr.2025.102267_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/crj.13262","article-title":"Delafloxacin-A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"15","author":"Millar","year":"2021","journal-title":"Clin. Res. J"},{"issue":"1","key":"10.1016\/j.rmcr.2025.102267_bib6","article-title":"A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.rmcr.2025.102267_bib7","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: a novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmcr.2025.102267_bib8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/antibiotics12061078","article-title":"Activity of delafloxacin and comparator fluoroquinolones against multidrug-resistant Pseudomonas aeruginosa in an in vitro cystic fibrosis sputum model","volume":"12","author":"Craddock","year":"2023","journal-title":"Antibiotics"},{"year":"2024","key":"10.1016\/j.rmcr.2025.102267_bib10"},{"key":"10.1016\/j.rmcr.2025.102267_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40101-021-00269-7","article-title":"The determinants of survival among adults with cystic Fibrosis\u2014a cohort study","volume":"40","author":"Durda-Masny","year":"2021","journal-title":"J. Physiol. Anthropol."},{"key":"10.1016\/j.rmcr.2025.102267_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcf.2020.10.008","article-title":"Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis","volume":"20","author":"Jackson","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmcr.2025.102267_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(24)00548-4","article-title":"P246 case report: use of the novel oral fluoroquinolone delafloxacin in cystic fibrosis","volume":"23","author":"Dooney","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmcr.2025.102267_bib14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/thoraxjnl-2011-200832","article-title":"Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols","volume":"67","author":"Taccetti","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmcr.2025.102267_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(18)30171-1","article-title":"The CF-Sputum induction trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial","volume":"6","author":"Ronchetti","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmcr.2025.102267_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1015","article-title":"Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol Res. Perspect."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125001030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125001030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:45:59Z","timestamp":1758127559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007125001030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"alternative-id":["S2213007125001030"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102267","relation":{},"ISSN":["2213-0071"],"issn-type":[{"type":"print","value":"2213-0071"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using delafloxacin, a 4th generation fluoroquinolone, in combination with nebulised tobramycin to eradicate Pseudomonas aeruginosa in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102267"}}